Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Novel missense mutations in the tyrosine kinase domain of the platelet-derived growth factor receptor α(PDGFRA) gene in childhood acute myeloid leukemia with t(8;21)(q22;q22) or inv(16)(p13q22)

Leukemia volume 19, pages 476–477 (2005)Cite this article

TO THE EDITOR

The class III receptor tyrosine kinases (RTKs), which include c-FMS, c-KIT, FLT3, platelet-derived growth factor receptor α (PDGFRA) and β (PDGFRB), have been reported to be associated with the pathogenesis of an increasing number of malignancies.1,2 PDGFRA and c-KIT are two related RTKs showing similar structure, and mutations of these genes are detected in gastrointestinal stromal tumor (GIST).3,4 Recently, a c-KIT D816V-activating mutation in the second tyrosine kinase (TK2) domain has been reported in patients having acute myeloid leukemia (AML) with t(8;21)(q22;q22) or inv(16)(p13q22).5 Hence, we speculated that PDGFRA is also implicated in the pathogenesis of AML, and the mechanisms of cytogenetic progression and oncoprotein-driven function may be similar in AML expressing oncogenic forms of PDGFRA and c-KIT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Blume-Jensen P, Hunter T . Oncogenic kinase signalling. Nature 2001; 411: 355–365.

    Article  CAS  PubMed  Google Scholar 

  2. Scheijen B, Griffin JD . Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 2002; 21: 3314–3333.

    Article  CAS  PubMed  Google Scholar 

  3. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708–710.

    Article  CAS  PubMed  Google Scholar 

  4. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577–580.

    Article  CAS  PubMed  Google Scholar 

  5. Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E et al. C-kit mutations in core binding factor leukemias. Blood 2000; 95: 726–727.

    CAS  PubMed  Google Scholar 

  6. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560–10564.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434–2439.

    Article  CAS  PubMed  Google Scholar 

  8. Spiekermann K, Bagrintseva K, Schoch C, Haferlach T, Hiddemann W, Schnittger S . A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood 2002; 100: 3423–3425.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr Kanji Sugita (Department of Pediatrics, Yamanashi University School of Medicine, Yamanashi, Japan) for providing ALL (KOCL-44, 45) cell lines, and Dr Yoshinobu Matsuo (Hayashibara Biochemical Laboratories, Inc., Fujisaki Cell Center, Okayama, Japan) for providing varieties of ALL cell lines.

Author information

Authors and Affiliations

  1. Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Japan

    M Hiwatari

  2. Department of Molecular Laboratory Medicine, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Japan

    T Taki

  3. Department of Pediatrics, Ibaraki Children's Hospital, Japan

    M Tsuchida

  4. Division of Hematology/Oncology, Saitama Children's Medical Center, Japan

    R Hanada

  5. Department of Pediatrics, Hamamatsu University School of Medicine, Japan

    T Hongo

  6. Department of Pediatrics, Osaka City General Hospital, Japan

    M Sako

  7. Gunma Children's Medical Center, Kitatachibana, Gunma, Japan

    Y Hayashi

Authors
  1. M Hiwatari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Taki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Tsuchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Hanada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Hongo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Sako
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Hayashi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hiwatari, M., Taki, T., Tsuchida, M. et al. Novel missense mutations in the tyrosine kinase domain of the platelet-derived growth factor receptor α(PDGFRA) gene in childhood acute myeloid leukemia with t(8;21)(q22;q22) or inv(16)(p13q22). Leukemia 19, 476–477 (2005). https://doi.org/10.1038/sj.leu.2403638

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403638

This article is cited by

Search

Advanced search

Quick links